C Fernández-Espartero1, E de Miguel2, E Loza3, E Tomero4, M Gobbo5, M A Descalzo5, E Collantes-Estévez6, J Mulero7, S Muñoz-Fernández8, P Zarco9, L Carmona10. 1. Rheumatology Department, Hospital Universitario de Móstoles, Madrid, Spain. 2. Rheumatology Department, Hospital Universitario de la Paz, Madrid, Spain. 3. Institute for Musculoskeletal Health, Madrid, Spain. 4. Rheumatology Department, Hospital Universitario de la Princesa, Instituto de Investigación La Princesa, Madrid, Spain. 5. Research Unit, Fundación Española de Reumatología, Madrid, Spain. 6. Rheumatology Department, Hospital Universitario Reina Sofía, Instituto Mainónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain. 7. Rheumatology Department, Hospital Universitario de Puerta de Hierro-Majadahonda, Madrid, Spain. 8. Rheumatology Department, Hospital Universitario Infanta Sofía, Madrid, Spain. 9. Rheumatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain. 10. Institute for Musculoskeletal Health, Madrid, Spain Universidad Camilo José Cela, Madrid, Spain.
Abstract
OBJECTIVES: To evaluate the validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in early spondyloarthritis (SpA) in comparison with conventional clinical measures of disease activity. METHODS: Six hundred and seventy-six incident cases of early SpA from the Esperanza programme were included. Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and on the physician's decision to start treatment with a disease-modifying antirheumatic drug or tumour necrosis factor blocker. The discriminant ability of ASDAS-C-reactive protein (CRP) and ASDAS-erythrocyte sedimentation rate (ESR) was tested using standardised mean differences between patients with high and low disease activity. Convergent validity was tested by Pearson correlation between ASDAS versions and other measures of disease activity. RESULTS: ASDAS-ESR and ASDAS-CRP showed good correlation with BASDAI (r=0.79 and 0.74, respectively). Both indices correlated well with the patient global assessment (r=0.70 in both indices) and moderately with the physician global score (r=0.46 and 0.47, respectively). CRP and ESR showed poor correlation with patient- and physician-derived measures. ASDAS performed similarly across the global SpA sample, ankylosing spondylitis (AS), non-radiographic axial SpA and peripheral SpA. CONCLUSIONS: ASDAS performed as a valid activity score even being slightly better than the Bath Ankylosing Spondylitis Disease Activity Index in its ability to discriminate between high and low disease activity in early SpA. ASDAS performed similarly in AS, early forms of SpA, non-radiographic axial SpA and peripheral SpA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: To evaluate the validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in early spondyloarthritis (SpA) in comparison with conventional clinical measures of disease activity. METHODS: Six hundred and seventy-six incident cases of early SpA from the Esperanza programme were included. Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and on the physician's decision to start treatment with a disease-modifying antirheumatic drug or tumour necrosis factor blocker. The discriminant ability of ASDAS-C-reactive protein (CRP) and ASDAS-erythrocyte sedimentation rate (ESR) was tested using standardised mean differences between patients with high and low disease activity. Convergent validity was tested by Pearson correlation between ASDAS versions and other measures of disease activity. RESULTS: ASDAS-ESR and ASDAS-CRP showed good correlation with BASDAI (r=0.79 and 0.74, respectively). Both indices correlated well with the patient global assessment (r=0.70 in both indices) and moderately with the physician global score (r=0.46 and 0.47, respectively). CRP and ESR showed poor correlation with patient- and physician-derived measures. ASDAS performed similarly across the global SpA sample, ankylosing spondylitis (AS), non-radiographic axial SpA and peripheral SpA. CONCLUSIONS: ASDAS performed as a valid activity score even being slightly better than the Bath Ankylosing Spondylitis Disease Activity Index in its ability to discriminate between high and low disease activity in early SpA. ASDAS performed similarly in AS, early forms of SpA, non-radiographic axial SpA and peripheral SpA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Agustí Sellas I Fernandez; Xavier Juanola Roura; Alberto Alonso Ruiz; José Rosas; Julio Medina Luezas; Eduardo Collantes Estevez; Miguel Ángel Abad Hernández; Virginia Carrasco Benitez; Cesar Fisac Journal: Rheumatol Int Date: 2017-09-16 Impact factor: 2.631
Authors: Wen Liu; Keshav Raj Sigdel; Ying Wang; Qun Su; Yan Huang; Yan Lin Zhang; Jie Chen; Lihua Duan; Guixiu Shi Journal: PLoS One Date: 2015-07-16 Impact factor: 3.240
Authors: Roxana Rubio Vargas; Rosaline van den Berg; Miranda van Lunteren; Zineb Ez-Zaitouni; Pauline A C Bakker; Hanne Dagfinrud; Roberta Ramonda; Robert Landewé; Esmeralda Molenaar; Floris A van Gaalen; Désirée van der Heijde Journal: RMD Open Date: 2016-06-16